$2.57 Billion is the total value of Tekla Capital Management LLC's 187 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 21.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | Sell | Gilead Sciences, Inc. | $155,582,000 | -13.8% | 2,063,699 | -18.1% | 6.05% | -13.1% |
| CELG | Sell | Celgene Corporation | $120,687,000 | -23.6% | 1,352,842 | -10.6% | 4.69% | -23.0% |
| AMGN | Sell | Amgen Inc. | $119,436,000 | -20.3% | 700,588 | -18.7% | 4.64% | -19.7% |
| BIIB | Sell | Biogen Inc. | $103,696,000 | -27.0% | 378,703 | -15.0% | 4.03% | -26.3% |
| VRTX | Sell | Vertex Pharmaceuticals Incorporated | $100,083,000 | +3.7% | 614,084 | -4.6% | 3.89% | +4.6% |
| MRK | Sell | Merck & Co., Inc. | $69,941,000 | -6.0% | 1,284,022 | -2.9% | 2.72% | -5.2% |
| ALXN | Sell | Alexion Pharmaceuticals, Inc. | $55,616,000 | -29.5% | 498,975 | -24.4% | 2.16% | -28.9% |
| INCY | Sell | Incyte Corporation | $53,785,000 | -18.1% | 645,442 | -6.9% | 2.09% | -17.4% |
| REGN | Sell | Regeneron Pharmaceuticals, Inc. | $48,059,000 | -25.0% | 139,560 | -18.2% | 1.87% | -24.4% |
| HUM | Sell | Humana Inc. | $31,919,000 | -7.1% | 118,733 | -14.3% | 1.24% | -6.4% |
| NVS | Sell | Novartis AGsponsored adr | $28,380,000 | -11.5% | 351,020 | -8.1% | 1.10% | -10.8% |
| NBIX | Sell | Neurocrine Biosciences, Inc. | $23,172,000 | -8.1% | 279,419 | -14.0% | 0.90% | -7.4% |
| BMRN | Sell | BioMarin Pharmaceutical Inc. | $22,787,000 | -47.8% | 281,076 | -42.6% | 0.89% | -47.4% |
| TEVA | Sell | Teva Pharmaceutical Industries Limitedsponsored adr | $18,512,000 | -38.3% | 1,083,223 | -31.6% | 0.72% | -37.8% |
| SHPG | Sell | Shire plcsponsored adr | $17,274,000 | -44.8% | 115,629 | -42.7% | 0.67% | -44.3% |
| MCK | Sell | McKesson Corporation | $13,918,000 | -28.0% | 98,797 | -20.3% | 0.54% | -27.5% |
| XLRN | Sell | Acceleron Pharma Inc. | $10,678,000 | -11.2% | 273,098 | -3.6% | 0.42% | -10.6% |
| ADAP | Sell | Adaptimmune Therapeutics plcsponsored adr | $9,607,000 | +53.8% | 855,468 | -8.5% | 0.37% | +55.2% |
| CI | Sell | Cigna Corporation | $9,488,000 | -53.3% | 56,563 | -43.4% | 0.37% | -52.9% |
| CLLS | Sell | Cellectis S.A.sponsored adr | $8,925,000 | -1.3% | 283,250 | -8.7% | 0.35% | -0.6% |
| DPLO | Sell | Diplomat Pharmacy, Inc. | $8,846,000 | -31.2% | 439,001 | -31.5% | 0.34% | -30.6% |
| ABC | Sell | AmerisourceBergen Corporation | $7,992,000 | -48.0% | 92,707 | -44.6% | 0.31% | -47.5% |
| NVO | Sell | Novo Nordisk A/Ssponsored adr | $6,693,000 | -54.1% | 135,900 | -50.0% | 0.26% | -53.8% |
| QURE | Sell | uniQure N.V.shares | $4,694,000 | -28.0% | 199,750 | -40.0% | 0.18% | -27.4% |
| NVRO | Sell | Nevro Corp. | $4,593,000 | -65.8% | 52,990 | -72.8% | 0.18% | -65.4% |
| MYOV | Sell | Myovant Sciences Ltd. | $3,201,000 | -36.7% | 150,471 | -62.4% | 0.12% | -36.4% |
| ARGX | Sell | argenx SEsponsored adr | $3,132,000 | +6.7% | 38,931 | -16.2% | 0.12% | +8.0% |
| PRAH | Sell | PRA Health Sciences, Inc. | $2,693,000 | -54.4% | 32,460 | -50.0% | 0.10% | -53.9% |
| INVA | Sell | Innoviva, Inc. | $2,694,000 | -23.7% | 161,603 | -35.0% | 0.10% | -22.8% |
| CRL | Sell | Charles River Laboratories International, Inc. | $2,420,000 | -74.2% | 22,670 | -73.6% | 0.09% | -74.0% |
| CBAY | Sell | Cymabay Therapeutics, Inc. | $2,208,000 | +14.3% | 169,962 | -19.1% | 0.09% | +14.7% |
| ACAD | Sell | ACADIA Pharmaceuticals Inc. | $2,105,000 | -71.6% | 93,689 | -61.9% | 0.08% | -71.3% |
| LXRX | Sell | Lexicon Pharmaceuticals, Inc. | $1,980,000 | -28.1% | 231,054 | -17.1% | 0.08% | -27.4% |
| DERM | Sell | Dermira, Inc. | $1,871,000 | -74.9% | 234,200 | -12.8% | 0.07% | -74.7% |
| RARX | Sell | Ra Pharmaceuticals, Inc. | $1,798,000 | -40.6% | 338,565 | -5.0% | 0.07% | -40.2% |
| ONCE | Sell | Spark Therapeutics, Inc. | $1,468,000 | -26.2% | 22,046 | -43.0% | 0.06% | -26.0% |
| AMRN | Sell | Amarin Corporation plcsponsored adr | $1,439,000 | -62.5% | 478,149 | -50.0% | 0.06% | -62.2% |
| XENE | Sell | Xenon Pharmaceuticals Inc. | $1,372,000 | +38.7% | 280,000 | -20.0% | 0.05% | +39.5% |
| CYTK | Sell | Cytokinetics, Incorporated | $992,000 | -65.3% | 137,797 | -60.7% | 0.04% | -64.5% |
| NTRA | Sell | Natera, Inc. | $962,000 | -78.0% | 103,731 | -78.6% | 0.04% | -78.0% |
| CDTX | Sell | Cidara Therapeutics, Inc. | $635,000 | -67.4% | 158,784 | -44.6% | 0.02% | -66.7% |
| KPTI | Exit | Karyopharm Therapeutics Inc. | $0 | – | -20 | -100.0% | 0.00% | – |
| ZFGN | Exit | Zafgen, Inc. | $0 | – | -13,307 | -100.0% | -0.00% | – |
| EARS | Exit | Auris Medical Holding AG | $0 | – | -774,504 | -100.0% | -0.02% | – |
| IPXL | Exit | Impax Laboratories, Inc. | $0 | – | -124,335 | -100.0% | -0.08% | – |
| BCRX | Exit | BioCryst Pharmaceuticals, Inc. | $0 | – | -449,255 | -100.0% | -0.08% | – |
| ADVM | Exit | Adverum Biotechnologies, Inc. | $0 | – | -743,974 | -100.0% | -0.10% | – |
| CASC | Exit | Cascadian Therapeutics, Inc. | $0 | – | -740,769 | -100.0% | -0.11% | – |
| AGNPRA | Exit | Allergan plc5.50% convertible preferred series a | $0 | – | -5,000 | -100.0% | -0.11% | – |
| DXCM | Exit | DexCom, Inc. | $0 | – | -53,950 | -100.0% | -0.12% | – |
| Exit | Intercept Pharmaceuticals, Inc.note 3.250% 7/1/23 | $0 | – | -6,900,000 | -100.0% | -0.21% | – | |
| NUVA | Exit | NuVasive, Inc. | $0 | – | -117,437 | -100.0% | -0.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.